European cardiologists to review Multaq; Roche plots sale of Boulder plant;

@FiercePharma: Surprise Provenge shortfall triggers Dendreon layoffs. Story | Follow @FiercePharma

> The European Society of Cardiology will review its atrial fibrillation treatment guidelines in light of a recently halted Multaq trial that raised safety questions about using the Sanofi drug in patients with permanent AF. Report

> An Abbott Laboratories plant in Temecula, CA, is the first business to be admitted to a foreign trade zone with boundaries recently redrawn to help area companies. Item

> Roche plans to sell its 256-employee manufacturing plant in Boulder, CO, to International Chemical Investors Group for use by the company's Corden Pharma group. Story

> Enzon Pharmaceuticals posted a larger quarterly loss as royalties from its hepatitis C drug Pegintron dropped. News

> Aspen Pharmacare reportedly won 29% of a 485 million rand ($70 million) tender to supply the South African government with tuberculosis drugs. Article

> The cost of Medicare Part D is dropping, with beneficiaries paying an average of $30 per month for a plan. Piece

Biotech News

@FierceBiotech: Be the first to meet the 2011 Fierce 15. News | Follow @FierceBiotech

@JohnCFierce: Texas Gov. Rick Perry gets a stem cell treatment, then lobbies for the procedure. Article | Follow @JohnCFierce

@MaureenFierce: 104-year-old 'super ager' can thank her lucky genes. Article | Follow @MaureenFierce

> Takeda, Amylin pull plug on obesity trial. News

> Questionable timing: House pushes biotech tax breaks. Article

> Dendreon releases death-eaters into biotech sector stocks. Report

And Finally... Japanese scientists make working mouse sperm from embryonic stem cells. More